Company profile for Entrada Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Entrada, we value intellectual curiosity and enjoy the challenge of fighting the good fight: waking up each day to advance our science one step closer to helping patients and their caregivers who deserve better treatments. Entrada’s Endosomal Escape Vehicle (EEV™) technology represents a fundamental advancement to the design and development of intracellular biologics. Our therapeutic candidates exhibit high cellular upt...
At Entrada, we value intellectual curiosity and enjoy the challenge of fighting the good fight: waking up each day to advance our science one step closer to helping patients and their caregivers who deserve better treatments. Entrada’s Endosomal Escape Vehicle (EEV™) technology represents a fundamental advancement to the design and development of intracellular biologics. Our therapeutic candidates exhibit high cellular uptake, achieve highly efficient endosomal escape and are designed to be exquisitely specific to intracellular targets.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
6 Tide Street Boston, MA 02210
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/03/02/3247889/0/en/Entrada-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
02 Mar 2026

https://www.globenewswire.com/news-release/2026/02/17/3239084/0/en/Independent-Data-Monitoring-Committee-Recommends-Initiation-of-Cohort-2-at-the-Increased-Dose-of-12-mg-kg-in-Entrada-Therapeutics-ELEVATE-44-201-Study.html

GLOBENEWSWIRE
17 Feb 2026

https://www.globenewswire.com/news-release/2026/02/04/3231902/0/en/Entrada-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
04 Feb 2026

https://www.globenewswire.com/news-release/2026/01/08/3215189/0/en/Entrada-Therapeutics-Highlights-Progress-Across-its-Portfolio-of-RNA-based-Therapeutics-for-the-Treatment-of-Neuromuscular-and-Ocular-Diseases.html

GLOBENEWSWIRE
08 Jan 2026

https://www.globenewswire.com/news-release/2025/12/17/3206850/0/en/Entrada-Therapeutics-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

GLOBENEWSWIRE
17 Dec 2025

https://www.globenewswire.com/news-release/2025/12/04/3200366/0/en/Entrada-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
04 Dec 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty